Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1-Reference-Cited by-同舟云学术

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

Published:2012-07-06 Issue:31 Volume:109 Page:E2127-E2133
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proceedings of the National Academy of Sciences

Author:

Ohashi K.,Sequist L. V.,Arcila M. E.,Moran T.,Chmielecki J.,Lin Y.-L.,Pan Y.,Wang L.,de Stanchina E.,Shien K.,Aoe K.,Toyooka S.,Kiura K.,Fernandez-Cuesta L.,Fidias P.,Yang J. C.-H.,Miller V. A.,Riely G. J.,Kris M. G.,Engelman J. A.,Vnencak-Jones C. L.,Dias-Santagata D.,Ladanyi M.,Pao W.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference43 articles.

1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

3. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

4. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

5. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Cited by 408 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents;Bioorganic Chemistry;2024-10

2. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

3. Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer;Frontiers in Pharmacology;2024-07-29

4. Pathways and targeting avenues of BRAF in non-small cell lung cancer;Expert Opinion on Therapeutic Targets;2024-07-02

5. ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework;npj Precision Oncology;2024-03-14